The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia
β-thalassemia is characterized by reduced or absence of β-globin production, resulting in anemia. Current therapies include blood transfusion combined with iron chelation. BM transplantation, although curative, is restricted by the matched donor limitation. Gene therapy, on the other hand, is promis...
Saved in:
Main Authors: | Ekati Drakopoulou, Eleni Papanikolaou, Nicholas P. Anagnou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.4061/2011/987980 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of Fractional Order Mathematical Model of Hematopoietic Stem Cell Gene-Based Therapy
by: Mohammad Imam Utoyo, et al.
Published: (2018-01-01) -
Exercise as an Adjuvant Therapy for Hematopoietic Stem Cell Mobilization
by: Russell Emmons, et al.
Published: (2016-01-01) -
Identification of β-globin gene mutations among transfusion-dependent β-thalassemia patients
by: Haidar Hussein Al-Fatlawi, et al.
Published: (2024-12-01) -
Ineffective Erythropoiesis in β-Thalassemia
by: Jean-Antoine Ribeil, et al.
Published: (2013-01-01) -
Physiopathology of Bone Modifications in β-Thalassemia
by: Carlo Perisano, et al.
Published: (2012-01-01)